



## Cryosurgical and Radiofrequency Ablation for Renal Tumors

**Last Review Date:** June 9, 2017

**Number:** MG.MM.SU.45C10

### Medical Guideline Disclaimer

Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ("EmblemHealth") has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc.

### Definitions

Cryoablation	Also known as cryosurgery or cryotherapy, cryoablation is a technique of ablating cells using liquid nitrogen or argon gas that is circulated through a hollow probe placed in direct contact with the tumor. An ice crystal formation around the probe tip freezes nearby cells, which destroys them. The ablated tissue is then absorbed by the body.
Radiofrequency ablation (RFA)	A technique of heating cells using a small needle electrode placed directly into a tumor. High frequency radio waves heat the tumor and cause local necrosis. The dead cells become scar tissue and eventually shrink.

### Guideline

Members with small undefined renal lesions ( $\leq 4$  cm in diameter) that are suspected to be malignant, or with malignant potential, are eligible for coverage of either cryoablation or RFA by any modality (eg laparoscopically or percutaneously) when either of the following criteria is met:

1. Medically or surgically inoperable tumor(s).
2. Poor candidacy for standard treatments (i.e., nephrectomy).

### Limitations/Exclusions

Neither cryoablation nor RFA is considered medically necessary for members able to undergo surgical resection.

**Applicable Procedure Codes**

50250	Ablation, open, one or more renal mass lesion(s), cryosurgical, including intraoperative ultrasound guidance and monitoring, if performed
50542	Laparoscopy, surgical; ablation of renal mass lesion(s), including intraoperative ultrasound guidance and monitoring when performed
50592	Ablation, one or more renal tumor(s), percutaneous, unilateral, radiofrequency
50593	Ablation, renal tumor(s), unilateral, percutaneous, cryotherapy

**Applicable ICD-10 Diagnosis Codes**

C64.1	Malignant neoplasm of right kidney, except renal pelvis
C64.2	Malignant neoplasm of left kidney, except renal pelvis
C64.9	Malignant neoplasm of unspecified kidney, except renal pelvis
C65.1	Malignant neoplasm of right renal pelvis
C65.2	Malignant neoplasm of left renal pelvis
C65.9	Malignant neoplasm of unspecified renal pelvis
D41.00	Neoplasm of uncertain behavior of unspecified kidney
D41.01	Neoplasm of uncertain behavior of right kidney
D41.02	Neoplasm of uncertain behavior of left kidney
D41.10	Neoplasm of uncertain behavior of unspecified renal pelvis
D41.11	Neoplasm of uncertain behavior of right renal pelvis
D41.12	Neoplasm of uncertain behavior of left renal pelvis

**References**

National Cancer Institute. Renal Cell Cancer Treatment PDQ<sup>®</sup> Health Professional Version. April 2016.  
<http://www.cancer.gov/cancertopics/pdq/treatment/renalcell/healthprofessional>. Accessed June 13, 2017.

National Institute for Clinical Excellence. Laparoscopic cryotherapy for renal cancer. May 21 2012.  
<http://guidance.nice.org.uk/IPG405>. Accessed June 13, 2017.

National Institute for Clinical Excellence. Percutaneous cryotherapy for renal tumors. July 2011.  
<http://guidance.nice.org.uk/IPG402>. Accessed June 13, 2017.

National Institute for Clinical Excellence. Percutaneous Radiofrequency Ablation of Renal Cancer. July 2010.  
<http://guidance.nice.org.uk/IPG353>. Accessed June 13, 2017.

Specialty-matched clinical peer review.